“An Oral, Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib (BMS-986165), Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis”. SKIN The Journal of Cutaneous Medicine 4, no. 6 (October 27, 2020): s73. Accessed July 3, 2024. https://jofskin.org/33014/index.php/skin/article/view/1106.